Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.

Saved in:
Bibliographic Details
Title: Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Authors: Esteve-Pastor MA; Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, 30120 Murcia, Spain., Rivera-Caravaca JM; Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, 30120 Murcia, Spain., Roldán V; Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, 30008 Murcia, Spain., Sanmartin Fernández M; Department of Cardiology, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain., Arribas F; Department of Cardiology, Hospital Universitario 12 de Octubre; Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid (UCM); Instituto de Investigacion Sanitaria Hospital 12 de Octubre (IMAS 12); CIBERCV, 28041 Madrid, Spain., Masjuan J; Department of Neurology, University Hospital Ramón y Cajal, Madrid. Alcalá University, 28034 Madrid, Spain., Barrios V; Department of Cardiology, University Hospital Ramón y Cajal, Madrid. Alcalá University, 28034 Madrid, Spain., Cosin-Sales J; Department of Cardiology, Hospital Arnau de Vilanova, 46015 Valencia, Spain., Freixa-Pamias R; Department of Cardiology, Hospital Moisés Broggi, 08970 Barcelona, Spain., Recalde E; Department of Cardiology, Hospital Universitario de Basurto, 48013 Bilbao, Spain., Pérez-Cabeza AI; Department of Cardiology, Hospital Universitario Virgen de la Victoria, CIBERCV, 29010 Málaga, Spain., Manuel Vázquez Rodríguez J; Department of Cardiology, Complejo Hospitalario Universitario A Coruña, INIBIC, CIBERCV, 15006 A Coruña, Spain., Ràfols Priu C; Department of Medical Affairs, Bayer Hispania, 08970 Barcelona, Spain., Anguita Sánchez M; Department of Cardiology, Hospital Reina Sofía Córdoba, IMIBIC, University of Cordoba, 14004 Córdoba, Spain., Lip GYH; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, L69 7TX Liverpool, UK.; Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark., Marin F; Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, 30120 Murcia, Spain.
Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2022 Dec 15; Vol. 9 (1), pp. 38-46.
Publication Type: Multicenter Study; Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium: Internet ISSN: 2055-6845 (Electronic) NLM ISO Abbreviation: Eur Heart J Cardiovasc Pharmacother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2055-6845
DOI:10.1093/ehjcvp/pvac060